Skip to main content

Advanced Search

Advanced Search

Current Filters

Filter your query

Publication Types



Newsletter Article


Study: Market Protections for Brand-Name Drugs Sustain High Prices

market exclusivity for prescription drugs in the US

Some policymakers have proposed extending the period during which brand-name pharmaceutical manufacturers can sell their products without facing competition from generic drug makers. But new Commonwealth Fund–supported research led by Aaron S. Kesselheim, M.D. (JAMA Internal Medicine, Sept. 11, 2017) calls into question the impact of additional protections intended to spur further investment in new therapeutics, given that brand-name manufacturers already receive 12 to 16 years of market exclusivity, on average. 

Publication Details